EuroNanoMed (ENM) is an ERA-NET on Nanomedicine established since 2008 as a platform for funding agencies and ministries to coordinate research and innovation programmes with the goal of creating and funding collaborative research and innovation projects that can convert research in nanotechnology into practical gains in medicine.
Through 8 successful Joint Transnational Calls launched from 2009 to 2017, EuroNanoMed has allocated about 67 Million euros to fund 76 transnational projects in nanomedicine.
Under the umbrella of EuroNanoMed III, the 9th Joint Transnational Call will be launched for funding multilateral innovative research projects on nanomedicine.
Research project consortia who intend to submit a transnational proposal should register at https://secure.pt-dlr.de/ptoutline/app/euronanomed2018, clicking the “to register” button and following the directions. The system will be opened by December 14, 2017. To register, please complete the different sections as soon as possible. Electronic proposal submission of proposals on the indicated website is mandatory.
Contact details for the Joint Call Secretariat:
JCS 2018 is hosted by The National Institute of Health Carlos III:
Monforte de Lemos, 5; 28029 Madrid, Spain
Contact person for the Joint Call Secretariat: María Druet
Email: firstname.lastname@example.org; Phone: +34 9182 22530
The aims of the call are:
Project proposals will address multidisciplinary and translational research. The project proposals must cover at least one of the following areas that are equal in relevance for this call:
Applicants are asked to specify to which of the two categories described below the project falls, according to its TRL, degree of innovation and expected time to market:
Joint research proposals may be submitted by applicants belonging to one of the following categories:
Each application should include partners from at least two of the three categories A, B and C. Each consortium submitting a proposal must involve a minimum of three eligible and a maximum of five eligible partners from at least three different countries participating to the. The maximum number of partners can be increased from five to seven under certain circumstances. No more than two eligible partners from the same country participating in the call will be accepted in one consortium.
Please note! Whilst applications will be submitted jointly by groups from several countries, individual groups will be funded by the individual EuroNanoMed funding organization respective of the country/region from which applicants have applied. The applications are therefore subjected to eligibility criteria of individual funding organizations. Please note that the national eligibility conditions have evolved since the last EuroNanoMed call. Applicants are therefore strongly advised to contact their national representative as soon as possible in order to confirm their eligibility with their respective funding organizations.
Have a look at the European Nanomedicine Map: http://www.etp-nanomedicine.eu/public/nanomedmap/
And our partner search tool: https://www.euronanomed.net/partner-search/list-of-searches-and-offers/
|Country||Funding Organisation||Contact point|
|Canada (Québec)||FRQS||Anne-Cécile Desfaits||Annececile.email@example.com|
|Germany||VDI Technologiezentrum GmbH||Olaf Rotthaus
|Spain||CDTI||Juan Luis Romerafirstname.lastname@example.org|
EURONANOMED PRP MEMBERS JTC 2018
|Todd Giorgio||Cancer Biology Vanderbilt University, US|
|Eliana Barbosa Souto||Faculty of Pharmacy – University of Coimbra, Portuga|
|María J. Blanco-Prieto||University of Navarra, Spain|
|Kristian Berg||Oslo University Hospital, Norway|
|Paolo Decuzzi||Istituto Italiano di Tecnologia, Italy|
|Philippe Bourrinet||Guerbet, France|
|Sara Eyal||Hebrew University, Israel|
|Maria Kempe||Lund University, Sweden|
|Thymios A. Mitsiadis||University of Zurich, Switzerland|
|Joao Nuno Moreira||University Coimbra – CNC, Portugal|
|Jan Mous||Pharmida AG, Switzerland|
|Giovanna Orsini||Polytechnic University of Marche, Italy|
|Haluk Külah||Middle East Technical University, Electrical and Electronics Engineering, Turkey|
|Elżbieta Pamuła||AGH University of Science and Technology. The Department of Biomaterials, Poland|
|Jürgen Schnekenburger||University Clinics Münster, Germany|
|Sven Schreder||Boehringer Ingelheim Pharma GmbH&Co. KG, Germany|
|Raymond Schiffelers||Laboratory Clinical Chemistry & Hematology Utrecht, The Netherlands|
|Hari Shanker Sharma||Uppsala University, Sweden|
|Stephan Stern||National Cancer Institute, USA|
Ⓒ All rights reserved EuroNanoMed III, 2018